vyndaqel signific upsid driver
chang stori
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
pfizer expand rare diseas unit featur vyndaqel recent launch
us show strong initi demand ahead consensu
vyndaqel indic orphan diseas call attr transthyretin amyloidosi
amyloid aggreg build cardiac neurolog tissu like mani orphan
diseas investor question size opportun given strong price
annual narrow patient popul patient global low
diagnosi rate end look valid size attr-cm opportun
upsid vyndaqel could bring share consensu forecast arent low
see potenti much higher sale pfizer help rais
diagnosi rate today prior launch typic orphan diagnosi rate
blue sky scenario estim vyndaqel sale could reach
inclus attr-cm us ou well attr-pn ou abil
leverag non-invas test combin limit market entrant sever year
see chart favor price eas oral administr would key
drive upsid vyndaqel expect base attr market analysi
product kol feedback weve updat vyndaqel forecast
ahead street see chart sale peak
havent adopt blue sky scenario inform next year metric
around diagnosi penetr reimburs despit higher sale good upsid
potenti vyndaqel doesnt yet move needl dcf given loe
period support neutral rate po
sky scenario vyndaqel still needle-mov
vyndaqel could vastli exceed expect noteworthi blue sky
scenario would contribut increment dcf valu share see
tabl order off-set loe period blue sky scenario would need
coupl strong growth biosimilar vaccin franchis longer
durat off-set loe impact accordingli suspect share wont
see much re-rat current peer greater clariti
franchis adjuv breast cancer phase data matur ibranc
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag
shed low growth busi divis
upjohn consum focus higher
growth innov busi compani look
return growth serv base
year revenu grow howev key
pipelin win necessari second wave
put growth risk
neutral await transact
close pipelin matur off-set
transthyretin natur occur proteinpredominantli produc liver
import transport thyroid hormon vitamin bodi
nativ transthyretin typic found tetram compos four subunit
blood protein may becom unstabl age wild type genet
predispos destabil hereditari type tetram destabil break
individu compon amyloid monom monom aggreg
non-funct clump tissu primarili cardiac tissu nervou
tissu vyndaqel oral small molecul approv medicin cardiomyopathi
form diseas stabil transthyretin tetram form therebi reduc
format amyloid fibril two drug current approv
polyneuropathi form diseas impact nervou system onpattro
transthyretin-direct small interf rna dose everi week intraven
infus tegsedi transthyretin-direct antisens oligonucleotid dose
market assumpt upsid
baselin assumpt includ attr-cm patient popul us
manag note see quot despit low current diagnosi rate
august rare diseas compani abl diagnos patient
given baselin model assum diagnosi rate increas
attr-cm popul us stay constant thereaft
assum price per year gross-to-net ou assum
patient expect peak diagnosi rate occur
sinc vyndaqel alreadi approv eu attr-pn cost
know benchmark quot past show diagnosi rate
rare diseas achiev drove
peak estim howev learn tremend amount everi singl day
particular diseas take diagnos certainli focus make
sure better patient pfizer call
blue sky scenario anticip similar patient popul base case
us ou maximum diagnosi rate us ou
assumpt would suggest scenario peak sale would still
allow competit entrant assum peak penetr diagnos
patient us loe ou loe
condit common year age believ next ten year
number go huge alreadi increas fast cardiomyopathi physician
scenario reli improv diagnosi attr-cm
readili avail scintigraphi techniqu scan organ histor
condit diagnos invas test cardiac tissu biopsi confirm
diagnosi limit treatment option avail vyndaqel approv
non-invas scintigraphi avail combin drive vast increas
diagnosi rateswhich wit thu far see quot
pleas see to-dat diagnosi driven
chart vyndaqel bofa merril lynch estim vs consensu million
reduc dose unlik impact sale
phase attr-act studi vyndaqel assess adult patient attr-cm
variant wild type random vyndaqel vyndaqel
placebo month pool vyndaqel compar placebo somewhat
surprisingli combin all-caus mortal cardiovascular-rel
hospit month vs placebo statist signific
dose dose also signific
differ safeti dose howev independ assess
endpoint all-caus mortal significantli reduc dose
trend toward reduct dose versu placebo
addit statist signific reduct n-termin pro hormon
bnp nt-probnp dose compar dose
placebo thu base avail data dose prefer
vyndaqel recommend dose daili four pill packag
come pill suppli bear case franchis could
patient tri reduc overal cost take one dose once-daili lower
cost drug per year certainli see scenario
patient may look question whether payer pharmaci benefit
manag pbm would push given lack statist benefit all-caus mortal
dose well reduct nt-probnp seen dose
overal would expect vyndaqel dose util vast major
patient given improv efficaci similar safeti profil also produc
vyndamax once-daili oral dose administ singl pill
problem get tafamidi approv patient assist
issu reimburs front cardiomyopathi physician
vyndaqel assumptionsboth base-cas blue-skyleav plenti room
competit entrant attr-cm space seen tabl main competitor
vyndaqel/vyndamax eido alnylam onpattro vutrisiran
competit entrant radar note number market dynam play
approv may tafamidi dose taken singl capsul
approv may tafamidi meglumin dose daili pill
on-going phase random double-blind placebo-control studi efficaci safeti
patient symptomat attr-cm attribute-cm primari complet expect primari endpoint
minut walk test month total death due all-caus frequenc cardiac-rel hospit
on-going phase random double-blind placebo-control studi evalu efficaci safeti patisiran
patient attr-cm apollo-b primari complet expect primari endpoint chang baselin
six-minut walk test
expect phase helios-b studi initi
clinic trial suspend due platelet reduct tegsedi approv attr-pn carri blackbox
warn thrombocytopenia glomerulonephr well rem program
pre-investig new drug ind meet fda complet ind-en toxicolog studi
initi ind expect submit
see number tailwind play favor competit
landscap attr-cm asset unlik significantli enter market
earliest leav three four year head start captur market
share note eido pursu acceler approv base interim
phase readout await detail whether clinic signific six-
minut walk test enough payer recommend use without data all-
caus mortal hospit month addit onpattro util
endpoint six-minut walk test cardiac/hospit data
secondari endpoint thu expect data impact mute
product base case scenario believ diagnos us
attr-cm popul ou attr-cm popul assum
vyndaqel penetr diagnos patient us
diagnos patient ou leav plenti room competit entrant space
one key clinic achiev third quarter initi
apollo-b phase studi aim expand onpattro label includ cardiomyopathi
inherit wild-typ attr amyloidosi patient set enrol underway
studi posit plan seek regulatori approv expand label patisiran
approxim timeframe- alnylam call
anoth benefit vyndaqel conveni oral dose vyndaqel administ
dosefour pillsonc daili vyndamax one pill daili
benefici especi given typic patient older year old
report first cardiac symptom diseas onpattro convers current
approv attr-pn indic dose intraven everi three week
therefor see potenti given oral dose vyndaqel prefer
choic move intraven therapi patient fail treatment
howev case must look competit eido
vyndaqel dose oral twice daili bid provid patient
favor administr seen tabl eido phase trial drug
abl improv baselin serum ttr concentr day
cohort addit eido alnylam develop vutrisiran
dose subcutan everi three month could benefici
patient howev vutrisiran expect reach market
studi design discuss fda well mani expert investig
field agre readout could consid registr trial
continu readout studi adequ power support two-part
mean chang ttr concentr baselin day
addit see price differenti space price tag
vyndaqel annual compar per year onpattro current
approv attr-pn eido could come market price
captur market share expect approxim three year head start
gain uptak comfort clinician build brand loyalti comfort prescrib
colleagu inclin prefer silenc patisiran vutrisiran treatment
futur take note silenc trial includ underli tafamidi
use clinic trial cardiomyopathi physician expert
remainco base blend averag dcf analysi
price-to-earnings multipl base larg cap global therapeut group dcf use
wacc termin valu intrins valu price-to-earnings analysi
assum multipl ep estim vs peer larg reflect
higher growth expect yield intrins valu support po
downsid risk sale downsid would expect share declin upcom data
prevnar ibranc posit inabl pipelin overcom patent loe
 transact perceiv valu destruct
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
